COVID-19 NAb > ABSOL

본문 바로가기
ABSOL VET Contact Us Login
Language
  • · Korean
  • · English

COVID-19 NAb

본문

Absoludy COVID-19 Neutralizing Antibody
  • · Absoludy COVID-19 Neutralizing Antibody for ABSOL use is based on the principle of Fluorescence immunoassay detecting semi-quantita- tive value of SARS-CoV-2 Virus's neutralizing antibody.
  • · Measuring the level of COVID-19 Neutralizing Antibody is to help check the overall vaccine efficacy, compare efficacy of different vac- cine candidates, monitor longevity of protective immunity and lead to herd immunity.
COVID-19NAb_01.png

· Performance
Total Results for COVID-19 NAb Clinical Agreement
Result 'A' 2019-nCoV Assay
Positive Negative Total
Absoludy COVID-19 NAb Positive 27 0 27
Negative 0 10 10
Total 27 10 37
Clinical Sensitivity: 98%
Clinical Specificity: 99%

·Procedure
Sample: Serum or Plasma(heparin, K2 -EDTA), 40μL
COVID-19NAb_02.pngCOVID-19NAb_03.pngCOVID-19NAb_04.pngCOVID-19NAb_05.pngCOVID-19NAb_06.png

· Result & Interpretation
The result of two CH. is determined by ABSOL Cut-off Index (COI)
Test result is negative if COI is< 1.0 and positive if COI is ≥1.0 (Negative "<"1.0, Positive ≥1.0)
COVID-19NAb_07.png
COVID-19NAb_08.png

· Spectification
AMR 60~300 IU/mL
Performance Sensitivity: 100%, Specificity: 100%
Test time 5 min
Sample type Serum and Plasma(Li-heparin or K2-EDTA)
Sample Volume 40µL
Storage 2~8 °C
COVID-19NAb_09.png
· Spectification
Cartridge 20ea
Pretreatment Tube 20ea
Disposable tip 24ea
Code chip 1ea
Package Insert sheet 1ea
COVID-19NAb_10.png